Comparative Pharmacology
Head-to-head clinical analysis: BLUDIGO versus LYMPHAZURIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BLUDIGO versus LYMPHAZURIN.
BLUDIGO vs LYMPHAZURIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BLUDIGO is a selective inhibitor of the hedgehog signaling pathway, specifically targeting the Smoothened (SMO) receptor, thereby suppressing the transcription of glioma-associated oncogene (GLI) family members and downstream target genes involved in cell proliferation and survival.
Lymphazurin is a diagnostic dye composed of isosulfan blue. It is a hydrophilic molecule that selectively binds to serum albumin and is preferentially taken up by lymphatic vessels. When injected subcutaneously or intradermally, it enters the lymphatic system and stains the lymphatic vessels and nodes, allowing for visual identification during lymph node mapping and sentinel lymph node biopsy procedures.
Intravenous (IV) 5 mg/kg every 8 hours, infused over 90 minutes on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle.
0.1 mL (100 mcg) administered via submucosal injection in 3 divided doses into the distal submucosa surrounding the cervical os (12, 4, and 8 o'clock positions) at a depth of 3 mm, 10 minutes prior to the procedure.
None Documented
None Documented
12-15 hours; prolonged in renal impairment (up to 30 hours in CrCl <30 mL/min).
Terminal elimination half-life is 18–24 hours; prolonged in renal impairment (up to 40 hours in severe impairment), requiring dose adjustment.
Primarily renal (70-80% unchanged) and biliary (15-20% as glucuronide conjugates); fecal excretion <5%.
Primarily renal excretion as unchanged drug (approximately 70%) and as glucuronide conjugate (20%); negligible biliary or fecal elimination (<5%).
Category C
Category C
Diagnostic Dye
Diagnostic Dye